Dual-action treatment for fibrotic disease secures orphan drug status
Drug Discovery World
FEBRUARY 13, 2024
AM1476, a first-in-class, peripheral-acting serotonin receptor antagonist, has been granted US and EU Orphan Drug Designation as an anti-fibrotic treatment for systemic sclerosis. AM1476 is a selective peripheral-acting 5-HT2B receptor small molecule antagonist that can be delivered orally.
Let's personalize your content